Bainbridge Shannon A, Smith Graeme N
Department of Anatomy and Cell Biology, Faculty of Health Sciences, Botterell Hall, Queen's University, Kingston, Ontario, Canada K7L 3N6.
Free Radic Biol Med. 2005 Apr 15;38(8):979-88. doi: 10.1016/j.freeradbiomed.2004.11.002.
The enzyme heme oxygenase (HO) has been implicated in several physiological functions throughout the body including control of vascular tone and regulation of the inflammatory and apoptotic cascades as well as contributing to the antioxidant capabilities in several organ systems. These various properties attributed to HO are carried out through the catalytic products of heme degradation, namely carbon monoxide (CO), biliverdin, and free iron (Fe2+). As the newly emerging roles of HO in normal organ function have come to light, researchers in several disciplines have assessed the role of this enzyme in various physiological and pathological changes taking place in the human body over a lifetime. Included in this new wave of interest is the involvement of HO, and its by-products, in the normal function of the vital organ of pregnancy, the placenta. In this review the role of HO, and its catalytic products, will be examined in the context of pregnancy. The different isoforms of the HO enzyme (HO-1, HO-2, HO-3) have been localized throughout placental tissue, and have been shown to be physiologically active. The HO protein and more specifically its catalytic by-products (CO, biliverdin, and Fe2+) have been postulated to be involved in the maintenance of uterine quiescence throughout gestation, regulation of hemodynamic control within the uterus and placenta, regulation of the apoptotic and inflammatory cascades in trophoblast cells, and the maintenance of a balance of the oxidant-antioxidant status within the placental tissues. The association between this enzyme system, and its above-noted roles throughout pregnancy, with the hypertensive disorder of pregnancy preeclampsia (PET), will also be examined. It is hypothesized that a decrease in HO expression and/or activity throughout gestation would be capable of initiating several pathological processes involved in the etiology of PET. This hypothesis has led to further discussion emphasizing the possibility of novel therapeutic designs targeting this enzyme system for the treatment of PET.
血红素加氧酶(HO)参与了全身多种生理功能,包括控制血管张力、调节炎症和凋亡级联反应,以及在多个器官系统中发挥抗氧化作用。HO的这些多种特性是通过血红素降解的催化产物实现的,即一氧化碳(CO)、胆绿素和游离铁(Fe2+)。随着HO在正常器官功能中的新作用逐渐被发现,多个学科的研究人员评估了这种酶在人体一生中发生的各种生理和病理变化中的作用。这新一轮的研究兴趣包括HO及其副产物在妊娠重要器官——胎盘的正常功能中的作用。在这篇综述中,将探讨HO及其催化产物在妊娠背景下的作用。HO酶的不同同工型(HO-1、HO-2、HO-3)已定位在整个胎盘组织中,并已证明具有生理活性。据推测,HO蛋白,更具体地说是其催化副产物(CO、胆绿素和Fe2+)参与了整个妊娠期子宫静息的维持、子宫和胎盘内血流动力学控制的调节、滋养层细胞凋亡和炎症级联反应的调节,以及胎盘组织内氧化-抗氧化状态平衡的维持。还将研究这个酶系统及其在整个妊娠过程中的上述作用与妊娠高血压疾病子痫前期(PET)之间 的关联。据推测,整个妊娠期HO表达和/或活性的降低能够引发PET病因中涉及的几个病理过程。这一假设引发了进一步的讨论,强调了针对这个酶系统设计新型治疗方法来治疗PET的可能性。